Evaluating Response to High‐Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease

Publisher: John Wiley & Sons Inc

E-ISSN: 1755-5949|21|6|513-519

ISSN: 1755-5930

Source: CNS: NEUROSCIENCE AND THERAPEUTICS, Vol.21, Iss.6, 2015-06, pp. : 513-519

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content